Literature DB >> 29191840

Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.

Jesus Anampa1, Tamanna Haque2, Irina Murakhovskaya3, Yanhua Wang4, Kimo Bachiashvili2, Cristian Papazoglu2, Kith Pradhan5, Ulrich G Steidl6, Joseph A Sparano2, Amit Verma3,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29191840      PMCID： PMC5830378          DOI： 10.3324/haematol.2017.181941

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.

Authors:  J W Harbour; R X Luo; A Dei Santi; A A Postigo; D C Dean
Journal:  Cell       Date:  1999-09-17       Impact factor: 41.582

2.  Measurement of red cell lifespan and aging.

Authors:  Robert S Franco
Journal:  Transfus Med Hemother       Date:  2012-08-27       Impact factor: 3.747

3.  The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle.

Authors:  D W Goodrich; N P Wang; Y W Qian; E Y Lee; W H Lee
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

Review 4.  Evaluation of Macrocytic Anemias.

Authors:  Ralph Green; Denis M Dwyre
Journal:  Semin Hematol       Date:  2015-06-30       Impact factor: 3.851

5.  Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.

Authors:  Wan Sun; Peter J O'Dwyer; Richard S Finn; Ana Ruiz-Garcia; Geoffrey I Shapiro; Gary K Schwartz; Angela DeMichele; Diane Wang
Journal:  J Clin Pharmacol       Date:  2017-04-18       Impact factor: 3.126

6.  Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.

Authors:  Keith T Flaherty; Patricia M Lorusso; Angela Demichele; Vandana G Abramson; Rachel Courtney; Sophia S Randolph; M Naveed Shaik; Keith D Wilner; Peter J O'Dwyer; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2011-11-16       Impact factor: 12.531

7.  In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days.

Authors:  Janesh Pillay; Ineke den Braber; Nienke Vrisekoop; Lydia M Kwast; Rob J de Boer; José A M Borghans; Kiki Tesselaar; Leo Koenderman
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

Review 8.  Neutrophil kinetics in health and disease.

Authors:  Charlotte Summers; Sara M Rankin; Alison M Condliffe; Nanak Singh; A Michael Peters; Edwin R Chilvers
Journal:  Trends Immunol       Date:  2010-08       Impact factor: 16.687

9.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon
Journal:  Lancet Oncol       Date:  2016-03-03       Impact factor: 41.316

10.  Palbociclib and Letrozole in Advanced Breast Cancer.

Authors:  Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245
View more
  1 in total

1.  Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.

Authors:  Barbara Maurer; Tania Brandstoetter; Sebastian Kollmann; Veronika Sexl; Michaela Prchal-Murphy
Journal:  Haematologica       Date:  2021-10-01       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.